SAGITTA

SAGITTA contains imatinib mesylate, a second generation tyrosine kinase inhibitor, as hard capsules, is available in the following dosage forms: - 100mg capsules, packs of 60 - 400mg capsules, packs of 30

SAGITTA is indicated for the treatment of Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia chromosome positive acute lymphoblasti